Sponsor:
Immuneering Corporation
Code:
NCT05585320
Conditions
Advanced Solid Tumor
Pancreatic Adenocarcinoma
Malignant Melanoma (Cutaneous)
Non-small Cell Lung Cancer (NSCLC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IMM-1-104 Monotherapy (Treatment Group A)
IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)
IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
IMM-1-104 + dabrafenib (Treatment Group D)
IMM-1-104 + pembrolizumab (Treatment Group E)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Immuneering Corporation on 2025-04-22.